Dare Bioscience (NASDAQ:DARE) Posts Earnings Results, Beats Expectations By $0.13 EPS

Dare Bioscience (NASDAQ:DARE) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.13, Zacks reports. The firm had revenue of $0.15 million for the quarter, compared to analyst estimates of $0.03 million.

Here are the key takeaways from Dare Bioscience’s conference call:

• Daré said it expects to begin recording its first direct product revenue in June 2026 from Flora Sync LF5, with a broader launch of the DARE to RESTORE line helping transition the company into a revenue-generating stage.
• DARE to PLAY continues to advance commercially, with pre-fulfillment prescribing live across all 50 states and nationwide dispensing targeted for this summer through 503B partner Bravado. Management said provider interest at ACOG was strong and could support office stocking and broader adoption.
• The company reported a second consecutive positive DSMB review for Ovaprene, with no new safety concerns and pregnancy and tolerability data described as consistent with expectations. Daré still expects to complete enough enrollment in 2026 to keep a 2027 primary endpoint analysis within reach.
• DARE-HPV is set to move into a phase II clinical study in May, backed by ARPA-H funding and recent IND clearance. Management highlighted it as a potentially first-in-category treatment for high-risk HPV, a largely untreated market.
• Daré ended Q1 with about $18.5 million in cash and said it does not currently have 12 months of capital on hand without future financing or product revenue. The company emphasized that non-dilutive grants remain an important funding source alongside planned product launches.

Dare Bioscience Price Performance

Shares of Dare Bioscience stock traded down $0.69 during trading on Friday, hitting $2.17. 1,217,264 shares of the stock were exchanged, compared to its average volume of 1,377,150. The stock has a market cap of $31.60 million, a price-to-earnings ratio of -2.28 and a beta of 1.09. The firm’s 50-day moving average price is $1.99 and its 200 day moving average price is $1.92. Dare Bioscience has a 12-month low of $1.27 and a 12-month high of $9.19.

Institutional Trading of Dare Bioscience

A number of hedge funds and other institutional investors have recently bought and sold shares of DARE. Virtu Financial LLC purchased a new stake in Dare Bioscience during the third quarter worth approximately $37,000. Raymond James Financial Inc. increased its stake in Dare Bioscience by 810.6% in the third quarter. Raymond James Financial Inc. now owns 15,334 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 13,650 shares during the last quarter. Finally, LPL Financial LLC acquired a new stake in Dare Bioscience during the fourth quarter worth approximately $28,000. 6.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dare Bioscience in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Dare Bioscience has an average rating of “Hold” and a consensus price target of $10.00.

About Dare Bioscience

Dare Bioscience, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for women’s reproductive health. The company’s flagship development candidate is Ovaprene, a monthly, self-administered, non-hormonal contraceptive vaginal ring designed to offer an alternative to traditional hormone-based birth control methods. Through its proprietary intravaginal drug delivery platform, Dare seeks to address unmet medical needs in gynecology and contraception with products that prioritize efficacy, safety and ease of use.

In addition to its lead contraceptive program, Dare is advancing a pipeline of early-stage assets aimed at treating gynecologic conditions through local, non-systemic drug delivery.